Clinical trialNCT01853982TerminatedPhase 3Interventional

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

SponsorCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Enrollment4Ventilator-Associated Pneumonia (VAP)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (IV) ceftolozane/tazobactam with that of IV piperacillin/tazobactam in the treatment of ventilator-associated pneumonia (VAP) in adult participants .

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Obiamiwe Umeh, MD
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Facility name not stated
Herston, Queensland, Australia
Facility name not stated
Meadowbrook, Queensland, Australia
Facility name not stated
Nambour, Queensland, Australia
Facility name not stated
Southport, Queensland, Australia
Facility name not stated
Woolloongabba, Queensland, Australia

New Zealand

Facility name not stated
Auckland, New Zealand
Facility name not stated
Christchurch, New Zealand
Facility name not stated
Wellington, New Zealand

United States

Facility name not stated
Jacksonville, Florida, United States
Facility name not stated
Chicago, Illinois, United States
Facility name not stated
Baltimore, Maryland, United States
Facility name not stated
Duluth, Minnesota, United States
Facility name not stated
Omaha, Nebraska, United States
Facility name not stated
Jamaica, New York, United States
Facility name not stated
The Bronx, New York, United States
Facility name not stated
Cleveland, Ohio, United States
Facility name not stated
Oklahoma City, Oklahoma, United States
Facility name not stated
Abington, Pennsylvania, United States
Facility name not stated
Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ceftolozane →Piperacillin / tazobactam

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Jun 2013
Primary completion: 20 Nov 2013
Completion: 8 Dec 2013
Last update posted: 16 Nov 2018
Registered enrollment: 4
Registry id: NCT01853982

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.